OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer - Robson, ME; Im, SA; Senkus, E (Eur J Cancer, 2023)